Immutep Limited

NASDAQ:IMMP

Biotechnology

Healthcare
$0.37 +0.64%

+$0.00 today

Market cap
$55.01M
Beta
2.24
P/E (TTM)
-0.9
EPS (TTM)
-$0.06
52W Low $0.29High $3.53

Volume 3.10M

Average 13.46M

IMMP Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Immutep LimitedNASDAQ: IMMP

Income Tax Expense · Q2 FY2026 · quarter ended Dec 2025

Income tax expense remains negative

Q2 FY2026 income tax expense was A$0, compared with A$0 a year earlier.

Context

  • Income tax expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Income tax expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
A$0— QoQ
Last fiscal yearJun 2025
A$0— YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

AUD · from the income statement

Latest · FY2025
0 AUD
Year-over-year change
—

Income Tax Expense vs competitors

How IMMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Income tax expense amounts to 0.0% of revenue for IMMP, versus a peer median of 16.8%.
IMMP Competitors
Income Tax Expense for IMMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$89.84M USD+889.7%+153.5%41.3%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$962K USD+199.0%—16.8%
PRQRProQR Therapeutics N.V.LTM Mar 2026€18.99K EUR+109.5%-42.5%0.1%
IMMPImmutep LimitedFY2025A$0 AUD——0.0%
CADLCandel Therapeutics, Inc.LTM Mar 2026$0 USD———
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$0 USD———
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%——
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$0 USD———
CABACabaletta Bio, Inc.LTM Mar 2026$0 USD———
EDITEditas Medicine, Inc.LTM Mar 2026$0 USD——0.0%
MREOMereo BioPharma Group plcLTM Mar 2026-$94.84K USD+83.4%—19.0%
Peer median (excluding IMMP) —+109.5%+55.5%16.8%

Competitors are the stored peer set for IMMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue3.86M170.37K3.51M3.84M5.04M
Cost of Revenue17.24M2.06M2.06M41.55M61.41M
Gross Profit(13.37M)(1.89M)1.44M(37.7M)(56.37M)
Gross Margin-346.2%-1111.2%41.2%-981.4%-1117.6%
Research & Development17.24M31.34M28.79M41.55M61.41M
Selling, General & Admin6.28M7.21M14.08M8.85M8.64M
Operating Expenses18.3M32.55M44.94M50.4M70.06M
Depreciation & Amortization1.89M1.84M1.86M2.01M2.13M
EBITDA(17.77M)(31.87M)(39.57M)(44.54M)(62.88M)
EBITDA Margin-460.0%-18708.9%-1128.8%-1159.4%-1246.6%
Operating Income(31.68M)(33.94M)(77.69M)(88.1M)(126.42M)
Operating Margin-820.0%-19920.0%-2216.0%-2293.3%-2506.5%
Interest Income105.33K224.52K939K3.88M5.25M
Interest Expense9.83K92.43K20.4K30.59K24.01K
Other Income / Expenses1.77M1.63M37.79M45.39M64.99M
Income Before Tax(29.9M)(32.21M)(39.9M)(42.72M)(61.43M)
Pre-Tax Margin-774.1%-18906.5%-1138.0%-1111.9%-1218.0%
Income Tax Expense3334000
Net Income(29.9M)(32.21M)(39.9M)(42.72M)(61.43M)
Net Margin-774.1%-18906.5%-1138.0%-1111.9%-1218.0%
EPS (Basic)(0.49)(0.37)(0.44)(0.36)(0.42)
EPS (Diluted)(0.49)(0.37)(0.44)(0.36)(0.42)
Weighted Avg Shares60.43M86.23M90.06M119.99M145.58M
Weighted Avg Shares (Diluted)60.43M86.23M90.06M120.11M145.58M

Immutep Limited

NASDAQ:IMMP

Intrinsic Alpha fair value

Locked

Current Price

$0.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.